(2,2-dichloro-ethyl)-cyclohexane | 5173-61-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 英文名称: (2,2-dichloro-ethyl)-cyclohexane
• 英文别名: (2,2-Dichlor-aethyl)-cyclohexan；(β,β-Dichlorethyl)-cyclohexan；1,1-Dichlor-2-cyclohexylethan；(2,2-Dichloroethyl)cyclohexane；2,2-dichloroethylcyclohexane
• CAS: 5173-61-5
• 化学式: C₈H₁₄Cl₂
• 分子量: 181.105
• InChiKey: ZCYFGVLFJDLYCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  (2,2-dichloro-ethyl)-cyclohexane 在 水 、 magnesium oxide 作用下， 生成 环己基乙醛
  参考文献：
  名称：

  Condensation of Saturated Halides with Unsaturated Compounds. V. Condensation of Cycloalkyl Halides with Ethylene and with Vinyl Halides

  摘要：

  DOI：

  10.1021/ja01170a089
• 作为产物：
  描述：

  氯乙烯 、 氯代环己烷 在 三氯化铝 作用下， 生成 (2,2-dichloro-ethyl)-cyclohexane
  参考文献：
  名称：

  Condensation of Saturated Halides with Unsaturated Compounds. V. Condensation of Cycloalkyl Halides with Ethylene and with Vinyl Halides

  摘要：

  DOI：

  10.1021/ja01170a089

文献信息

• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• PROCESS FOR EPROSARTAN INTERMEDIATE
  申请人：Parthasaradhi Reddy Bandi

  公开号：US20110054186A1

  公开（公告）日：2011-03-03

  The present invention provides an improved process for preparation of (E)-α-[[2-butyl-1-[[4-(methoxycarbonyl)phenyl]methyl]-1H-imidazole-5-yl]methylene]-2-thiophene propanoic acid ethyl ester in high purity and in high yield. Thus, for example, 4-[[2-butyl-5-formyl-1H-imidazole-1-yl]methyl]benzoic acid methyl ester is reacted with ethyl 2-carboxy-3-(2-thienyl)propionate in the presence of piperidinium propionate in diisopropyl ether or a mixture of n-hexane and a solvent selected from toluene and cyclohexane, optionally purifying the crude compound to obtain (E)-α-[[2-butyl-1-[[4-(methoxy carbonyl)phenyl]methyl]-1H-imidazole-5-yl]methylene]-2-thiophene propanoic acid ethyl ester substantially free of 3-(2-thienyl)propanoic acid ethyl ester impurity.

  本发明提供了一种改进的方法，用于制备高纯度和高产率的(E)-α-[[2-丁基-1-[[4-(甲氧羰基)苯基]甲基]-1H-咪唑-5-基]亚甲基]-2-噻吩丙酸乙酯。例如，将4-[[2-丁基-5-甲酰基-1H-咪唑-1-基]甲基]苯甲酸甲酯与丙酸2-羧基-3-(2-噻吩基)酯在哌啶丙酸盐存在下在二异丙醚或正己烷和甲苯或环己烷的混合溶剂中反应，可选地纯化粗化合物，以获得(E)-α-[[2-丁基-1-[[4-(甲氧羰基)苯基]甲基]-1H-咪唑-5-基]亚甲基]-2-噻吩丙酸乙酯，基本上不含3-(2-噻吩基)丙酸乙酯杂质。
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF PURE EPROSARTANAND ITS PHARMACEUTICAL ACCEPTABLE SALTS<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE L'EPROSARTAN PUR ET DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
  申请人：MATRIX LAB LTD

  公开号：WO2011051975A1

  公开（公告）日：2011-05-05

  The present invention relates to an improved process for preparation of pure Eprosartan and its pharmaceutical acceptable salts comprising the steps of: a) treating the Eprosartan with hydrochloric acid; b) suspending the resulted Eprosartan hydrochloride in water; c) adjusting the pH with base; d) isolating the pure Eprosartan; wherein the purity of the purified Eprosartan is higher than the purity of the starting Eprosartan.

  本发明涉及一种改进的制备纯Eprosartan及其药物可接受盐的方法，包括以下步骤：a）用盐酸处理Eprosartan；b）将所得的Eprosartan盐酸盐悬浮于水中；c）用碱调节pH值；d）分离纯Eprosartan；其中，纯化后的Eprosartan的纯度高于起始Eprosartan的纯度。
• PROCESS FOR EPROSARTAN
  申请人：Parthasaradhi Reddy Bandi

  公开号：US20100137613A1

  公开（公告）日：2010-06-03

  The present invention provides an improved and commercially viable process for preparation of eprosartan and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. Thus, for example, methyl 4-[[2-butyl-5-formyl-1 H-imidazol-1-yl]methyl]benzoate is reacted with ethyl 2-carboxy-3-(2-thienyl)propionate in the presence of a base, such as piperidine or piperidinium propionate in propionic acid, in cyclohexane solvent to give ethyl (αE)-α-[(2-n-butyl-1-[(4-(methoxy-carbonyl) phenyl]methyl]-1 H-imidazol-5-yl]methylene-2-thiophene propionate substantially free of decarboxylate impurity namely, ethyl 3-(2-thienyl)propionate, which is then subjected to base hydrolysis followed by treatment with methanesulfonic acid to obtain eprosartan mesylate in high purity and in high yield.

  本发明提供了一种改进的、商业上可行的方法，用于制备高纯度和高产率的依普罗沙坦及其药用盐酸盐。例如，将甲基4-[[2-丁基-5-甲酰基-1H-咪唑-1-基]甲基]苯甲酸酯与乙酸乙酯2-羧基-3-(2-噻吩基)丙酸酯在碱的存在下反应，例如在丙酸中的哌啶或哌啶丙酸盐的存在下，在环己烷溶剂中反应，得到乙酸乙酯(αE)-α-[(2-正丁基-1-[(4-甲氧羰基)苯基]甲基)-1H-咪唑-5-基]亚甲基-2-噻吩丙酸酯，其基本上不含脱羧杂质，即乙酸乙酯3-(2-噻吩基)丙酸酯，然后进行碱水解，随后用甲磺酸处理，得到高纯度和高产率的依普罗沙坦甲磺酸盐。
• [EN] PROCESS FOR THE PREPARATION OF EPROSARTAN<br/>[FR] PROCÉDÉ DE PRÉPARATION D’ÉPROSARTAN
  申请人：GLOCHEM IND LTD

  公开号：WO2011004384A2

  公开（公告）日：2011-01-13

  Disclosed herein is an improved novel synthetic process for the preparation of Eprosartan, which comprises treating 2-n-butyl-4-formylimidazole of formula (II) with N-protecting group selected from the group consisting of C1-C4 alkyl ester derivative of methacrylic acid; C1 -C4 alkyl ester derivative of crotonic acid; or C1 -C4 alkyl ester derivative of acrylic acid in the presence of a base selected from anion exchange resin or DBU and optionally in presence of a solvent, to get N-protected compound(III) in Stage-I. Stage-II comprises reacting N-protected compound (III) with 2-(2-thienyl methyl) propanedioic acid monoethyl ester to get compound (V). Stage-Ill comprises reacting compound(V) obtained from stage-II with methyl-4-(bromomethyl) benzoate to get compound (VII).Further, simultaneous hydrolysis of ester groups and removal of N-protecting group is accomplished using caustic soda solution, to yield Eprosartan of Formula (I) in Stage-IV. Finally, pharmaceutical acceptable salt of Eprosartan is prepared in Stage-V.

  本文披露了一种改进的新型合成过程，用于制备厄普罗沙坦。该过程包括在存在阴离子交换树脂或DBU的碱的条件下，将式（II）的2-n-丁基-4-甲酰基咪唑与从以下组中选择的N保护基进行处理：甲基丙烯酸酯的C1-C4烷基衍生物；巴豆烯酸酯的C1-C4烷基衍生物；或丙烯酸酯的C1-C4烷基衍生物，可选地在溶剂的存在下，获得N保护化合物（III），这是第一阶段。第二阶段包括将第一阶段获得的N保护化合物（III）与2-（2-噻吩甲基）丙二酸单乙酯反应，得到化合物（V）。第三阶段包括将从第二阶段得到的化合物（V）与甲基-4-（溴甲基）苯甲酸酯反应，得到化合物（VII）。进一步地，使用苛性钠溶液同时水解酯基和去除N保护基，以得到式（I）的厄普罗沙坦，这是第四阶段。最后，在第五阶段制备厄普罗沙坦的药用可接受盐。